Addressing fertility needs of breast cancer patients: oncology perspective

References

• Ries LAG, Eisner MP, Kosary Cl et al. SEER cancer statistics review. 1973–1999. National Cancer Institute, MD, USA (2002).
   Google Scholar
• Upponi SS, Ahmad F, Whitaker IS, Purushotham AD. Pregnancy after breast cancer. Eur. J. Cancer39, 736–741 (2003).
   PubMed Web of Science ®Google Scholar
• Walker RA, Lees E, Webb MB, Dearing SJ. Breast carcinoma occurring in young women (<35 yrs) are different. Br. J. Cancer7(Suppl. 4), 1796–1800 (1996).
   Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group: ovarian ablation in early breast cancer: overview of the randomised trials. Lancet348, 1189–1196 (1996).
   PubMed Web of Science ®Google Scholar
• Goldhirsch A, Gelber RD, Castilgione M. The magnitude of endocrine effects of adjuvant chemotherapy for premenopausal breast cancer patients. Ann. Oncol.1, 183–188 (1990).
   PubMed Web of Science ®Google Scholar
• Schover LR, Rybicki LA, Martin BA, Bringelsen KA. Having children after cancer: a pilot survey of survivors’ attitudes and experiences. Cancer86, 697–709 (1999).
   PubMed Web of Science ®Google Scholar
• Carter J, Rowland K, Chi D et al. Gynecologic cancer treatment and the impact of cancer-related infertility. Gynecol. Oncol.97, 90–95 (2005).
   PubMed Web of Science ®Google Scholar
• Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Knowledge and experience regarding cancer, infertility, and sperm banking in younger male survivors. J. Clin. Oncol.20, 1880–1889 (2002).
   PubMed Web of Science ®Google Scholar
• Schover LR, Brey K, Lichtin A, Lipshultz LI, Jeha S. Oncologists’ attitudes and practices regarding banking sperm before cancer treatment J. Clin. Oncol.20, 1890–1897 (2002).
   PubMed Web of Science ®Google Scholar
• Partridge AH, Gelber S, Peppercorn J et al. Web based survey of fertility issues in young women with breast cancer. J. Clin. Oncol.22, 4174–4183 (2004).
   PubMed Web of Science ®Google Scholar
• Speroff L, Glass RH, Kase NG. Clinical Gynaecologic Endocrinology and Infertility (6th Edition). Lippincott Williams and Wilkins, PA, USA (1999).
   Google Scholar
• Partridge A, Gelber S, Gelber RD, Castiglioe-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long term results from International Breast Cancer Study Group Trials V and VI. Eur. J. Cancer43, 1646–1653 (2007).
   PubMed Web of Science ®Google Scholar
• Oktay K, Oktem O, Reh A, Vahdat L. Measuring the impact of chemotherapy on fertility in women with breast cancer. J. Clin. Oncol.24, 4044–4046 (2006).
   PubMed Web of Science ®Google Scholar
• Beex LV, Mackenzie MA, Raemaekers JM, Smals AG, Benraad TJ, Kloppenborg PW. Adjuvant chemotherapy in premenopausal patients with primary breast cancer; relation to drug induced amenorrhoea, age and the progesterone receptor status of the tumour. Eur. J. Cancer Clin. Oncol.24, 719–721 (1988).
   Google Scholar
• Goodwin PJ, Ennis M, Pritchard KI, Trudeau M, Hood N. Risk of menopause during the first year after breast cancer diagnosis. J. Clin. Oncol.17, 2365–2370 (1999).
   PubMed Web of Science ®Google Scholar
• Walshe JM, Denduluri N, Swain S. Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer. J. Clin. Oncol.24, 5769–5779 (2006).
   PubMed Web of Science ®Google Scholar
• Basser RL, O’Neill A, Martinelli G et al. Multicycle dose intensive chemotherapy for women with high risk primary breast cancer: Results of International Breast Cancer Study Group trial 15–95. J. Clin. Oncol.24, 370–378 (2006).
   PubMed Web of Science ®Google Scholar
• Nitz UA, Mohrmann S, Fisher J et al. Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer. Results of a multicentre Phase III trial. Lancet366, 1935–1944 (2005).
   PubMed Web of Science ®Google Scholar
• Kramer R, Tham YL, Sexton K et al. Chemotherapy induced amenorrhea is increased in patients treated with adjuvant doxorubicin and cyclophosphamide (AC) followed by a taxane (T). J. Clin. Oncol.23(Suppl.), 651 (2005) (Abstract 651).
   Google Scholar
• Stone ER, Slack RS, Novielli A et al. Rate of chemotherapy related amenorrhea (CRA) associated with adjuvant adriamycin and cytoxan (AC) and adraimycin and cytoxan followed by taxol (AC+T) in early stage breast cancer. Breast Cancer Res. Treat.64, 61 (2000) (Abstract 224).
   Google Scholar
• Di Cosimo S, Alimonti A, Ferreti G et al. Incidence of chemotherapy induced amenorrhea depending on the timing of treatment by menstrual cycle phase in women with early breast cancer. Ann. Oncol.15, 1065–1071 (2004).
   PubMed Web of Science ®Google Scholar
• Glode LM, Robinson J, Gould SF. Protection from cyclophosphamide induced testicular damage with an analogue of gonadotropin – releasing hormone. Lancet1, 1132–1134 (1981).
   PubMed Web of Science ®Google Scholar
• Ataya K, Rao LV, Lawrence E, Kimmel R. Luteininsing hormone releasing hormone agonist inhibits cyclophosphamide induced ovarian follicular depletion in rhesus monkeys. Biol. Reprod.52, 365–372 (1995).
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z, Avivi I, Linn S, Epelbaum R, Ben-Shahar M, Haim N. Prevention of irreversible chemotherapy induced ovarian damage in young women with lymphoma by a gonadotropin releasing hormone agonist in parallel to chemotherapy. Hum. Reprod.11, 1620–1626 (1996).
   PubMed Web of Science ®Google Scholar
• Del Mastro L, Catzeddu T, Boni L et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppresion with goserolin in young, early breast cancer patients. Ann. Oncol.17, 74–78 (2006).
   PubMed Web of Science ®Google Scholar
• Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of GnRH agonist cotreatment in addition to cryopreservation of embrya, oocytes or ovaries. Oncologist12, 1044–1054 (2007).
   PubMed Web of Science ®Google Scholar
• Oktay K, Sonmezer M, Oktem O, Fox K, Emons G, Bang H. Absence of conclusive evidence for the safety and efficacy of gonadotropin releasing hormone analogue treatment in protecting against chemotherapy induced gonadal injury. Oncologist12, 1055–1066 (2007).
   PubMed Web of Science ®Google Scholar
• LHRH-agonists in Early Breast Cancer Overview group, Cuzick J, Ambroisine L et al. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone receptor-positive breast cancer: a meta analysis of individual patient data from randomised adjuvant trials. Lancet369, 1711–1723 (2007).
   PubMed Web of Science ®Google Scholar
• Lee SJ, Schover LR, Partridge AH et al. American Society of Clinical Oncology Recommendations on Fertility Preservation in Cancer Patients J. Clin. Oncol.24(18) 2917–2931 (2006).
   PubMed Web of Science ®Google Scholar
• Oktay K, Cil AP, Bang H The efficiency of oocyte cryopreservation. Fertil. Steril.86(1), 70–80 (2006).
   PubMed Web of Science ®Google Scholar
• Tachecki JJ, Cohen J. An overview of oocyte preservation. Reprod. Biomed. Online9, 152–163 (2004).
   Google Scholar
• Oktay K, Hourvitz A, Sahin G et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J. Clin. Endocrinol. Metab.91, 3885–3890 (2006).
   PubMed Web of Science ®Google Scholar
• Oktay K, Buyuk E, Libertella N, Akar M, Rosenwaks Z. Fertility preservation in breast cancer patients: a prospective controlled comparison of ovarian stimulation with tamoxifen and letrozole for embryo cryopreservation J. Clin. Oncol.23, 4347–4353 (2005).
   PubMed Web of Science ®Google Scholar
• Biljan M, Hemming R, Brassard N. The outcome of 150 babies following the treatment with letrozole or letrozole and gonadotropins. Fertil. Steril.84, S95 (2005).
   Web of Science ®Google Scholar
• Veronesi A, de Giacomi C, Magri MD et al. Familial breast cancer: characteristics and outcome of BRCA 1–2 positive and negative cases. BMC Cancer5, 70 (2005).
   Google Scholar
• Malamos NA, Stathopoulos GP, Keramopoulos A, Papadiamantis J, Vassilaros S. Pregnancy and offspring after the appearance of breast cancer. Oncology53, 471–475 (1996).
   PubMed Web of Science ®Google Scholar
• Ives A, Saunders C, Bulsara M, Semmens J. Pregnancy after breast cancer: population based study. BMJ334, 1–5 (2007).
   Google Scholar
• Jernstrom H, Lerman C, Ghadirian P et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet354, 1846–1850 (1999).
   PubMed Web of Science ®Google Scholar
• Hallowell N; Arden-Jones A, Eeles R et al. Guilt, blame and responsibility: men’s understanding of their role in the transmission of BRCA1/2 mutations within their family Social Health Illn.28(7), 969–988 (2006).
   PubMed Web of Science ®Google Scholar
• Verhaak CM, Smeenk JM, Evers AW, Kremer JA, Kraaimaat FW, Braat DD. Women’s emotional adjustment to IVF: a systematic review of 25 years of research. Hum. Reprod. Update13(1), 27–36 (2007).
   PubMed Web of Science ®Google Scholar
• Krychman ML, Pereira L, Carter J, Amsterdam A. Sexual oncology: sexual health issues in women with cancer. Oncology71(1–2), 18–25 (2006).
   PubMed Web of Science ®Google Scholar
• Pagani O, O’Neill A, Castiglione M et al. Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur. J. Cancer34(5), 632–640 (1998).
   PubMed Web of Science ®Google Scholar
• Ludwig Breast Cancer Study Group. A randomised trial of adjuvant combination chemotherapy with or without prednisolone in premenopausal breast cancer patients with metastases in one to three axillary lymph nodes. Cancer Res.45, 4454–4459 (1985).
   Google Scholar
• Jonat W, Kaufmann M, Sauerbrei W et al. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: the Zoladex Early Breast Cancer Research Association Study. J. Clin. Oncol.20(24), 4628–4635 (2002).
   PubMed Web of Science ®Google Scholar
• Castiglione-Gertsch M, O’Neill A, Price KN et al. Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: a randomized trial. J. Natl Cancer Inst.95(24), 1833–1846 (2003).
   PubMedGoogle Scholar
• Swain SM, Land SR, Novielli A et al. Amenorrhea in premenopausal women on the doxorubicin (A) and cyclophosphamide (C) – docetaxel (T) arm of NSABP B-30: preliminary results. J. Clin. Oncol.23(Suppl.), 13s (2005) (Abstract 537).
   Google Scholar
• Luporsi E, Weber B. The effects of breast cancer chemotherapy on menstrual function. Proc. Am. Soc. Clin. Oncol.17, 155A (1988) (Abstract 595).
   Google Scholar
• Roche H, Kerbrat P, Bonneterre J et al. Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial. Ann. Oncol.17(8), 1221–1227 (2006).
   PubMed Web of Science ®Google Scholar
• Martin M, Pienkowski T, Mackey J et al. Adjuvant docetaxel for node-positive breast cancer. N. Engl. J. Med.352(22), 2302–2313 (2005).
   PubMed Web of Science ®Google Scholar